Change search
ReferencesLink to record
Permanent link

Direct link
Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Jönköping University, School of Health and Welfare, HHJ, Institute of Gerontology.ORCID iD: 0000-0002-8212-823X
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
2016 (English)In: Multiple Sclerosis and Related Disorders, ISSN 2211-0348, E-ISSN 2211-0356, Vol. 10, 36-43 p.Article in journal (Refereed) Published
Abstract [en]

Background: Cognitive impairment in multiple sclerosis (MS) is common and has severe implications. Natalizumab (NZ) has documented effects on relapse rate and radiological disease activity in relapsing-remitting MS (RRMS) but studies regarding its specific effects on cognitive functioning are few. Previous studies have reported improvement, however, often lacking relevant control groups. The objective of the present study was to evaluate the cognitive effects of NZ treatment, compared to patients on stable first-line treatment and healthy control subjects.

Methods: MS patients starting NZ (MS-NZ), MS controls with stable interferon beta therapy (MS-C) and healthy control subjects (HC) were evaluated twice with one year interval, using a cognitive test battery covering six cognitive domains. The effects of NZ on levels of self-reported depression, fatigue, daytime sleepiness and perceived health were also examined.

Results: MS patients (MS-NZ and MS-C) had significantly lower baseline cognitive performance compared to HC (global score, p=0.002), but there were no significant differences between MS-NZ and MS-C. At follow-up, both MS-NZ and MS-C had improved significantly in four and five cognitive domains, respectively, and in global score (p=0.013 and p<0.001, respectively). HC improved significantly in three cognitive domains but not in global score. A regression analysis including baseline cognitive z-score and z-score change showed that participants with lower baseline scores had a significantly greater improvement, compared to those with better initial performance (p=0.021). There were no significant changes in depression, fatigue, daytime sleepiness or perceived health in MS-NZ or MS-C.

Conclusions: Initiation of NZ therapy did not result in true cognitive improvement over one year. Presumably, the increased test performance in both MS groups was artificial and due to retest effects that were stronger in patients with lower baseline performance. Adequate control groups are essential when evaluating cognitive functioning in intervention trials among RRMS patients.

Place, publisher, year, edition, pages
2016. Vol. 10, 36-43 p.
National Category
Neurology
Identifiers
URN: urn:nbn:se:hj:diva-31737DOI: 10.1016/j.msard.2016.08.011ISI: 000390826300008PubMedID: 27919496ScopusID: 2-s2.0-84984682091OAI: oai:DiVA.org:hj-31737DiVA: diva2:968063
Available from: 2016-09-12 Created: 2016-09-12 Last updated: 2017-01-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Wahlin, Åke
By organisation
HHJ, Institute of Gerontology
In the same journal
Multiple Sclerosis and Related Disorders
Neurology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 25 hits
ReferencesLink to record
Permanent link

Direct link